Sponsored Content for Nathan Smith

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
NEUROSCIENTIFIC NSB BNBWA Bulls N' Bears 26 May 2026

NeuroScientific hails 80% clinical response in Crohn’s stem cell program

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has reported strong clinical outcomes from its StemSmart stem cell therapy, with four of five patients with fistulising Crohn's disease achieving a clinical response and all showing improvement. The results build on earlier patient data and will help guide a planned phase two trial as the company continues its push towards commercial development.

NEUROSCIENTIFIC_Q-GEN_BNBWA Bulls N' Bears 17 Mar 2026

NeuroScientific readies stem cell supply boost for bowel disease trials

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has taken a major step towards scaling up its StemSmart stem cell therapy by launching its first manufacturing run with Australian cell therapy specialist Q-Gen. The milestone signals the start of transferring the company's patented production process to a clinical-scale facility capable of supplying future trials and potentially, commercial demand.

NEUROSCIENTIFIC_CROHNS_BNBWA Bulls N' Bears 13 Jan 2026

NeuroScientific Biopharmaceuticals soars on stem cell tech results

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Early-stage biotech NeuroScientific Biopharmaceuticals has delivered real-world promise for those living with chronic Crohn's disease following recent findings from its StemSmart cell therapy. Prescribed under Australia's Special Access Scheme, the results showed a strong clinical response in some of Crohn's disease's toughest patients, giving the company valuable validation, sharper trial design and a clearer pathway into a multi-billion-dollar global market.

NEUROSCIENTIFIC_NATHAN SMITH_BULLSNBEARWA Bulls N' Bears 11 Nov 2025

NeuroScientific widens chronic bowel disease stem cell therapy program

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has reached another clinical milestone, with a fourth Crohn's disease patient now receiving its patented StemSmart stem cell therapy for the chronic bowel disease under Australia's Special Access Scheme. The company says data from the real-world program will directly inform the design of its upcoming phase two trial, slated to begin in the second half of 2026.

NeuroScientific-Biopharmaceuticals-STEMSMART_BULLSNBEARSWA Bulls N' Bears 31 Jul 2025

NeuroScientific locks in deal to scale-up stem cell production

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals is transferring its patented StemSmart technology to one of Australia's biggest and most experienced manufacturers to scale up clinical-grade production, ahead of the commercialisation of its infusion therapy for hard-to-treat conditions, starting with Crohn's disease. Queensland-based Q-Gen Cell Therapeutics specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control.

X